GSK
January 31, 2024 - AI Summary
Overvalued by 29.1% based on the discounted cash flow analysis.
Market cap | $81.38 Billion |
---|---|
Enterprise Value | $97.74 Billion |
Dividend Yield | $1.4449 (3.68%) |
Earnings per Share | $3.05 |
Beta | 0.35 |
Outstanding Shares | 2,072,439,973 |
Avg 30 Day Volume | 2,925,320 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 12.96 |
---|---|
PEG | -15.86 |
Price to Sales | 2.27 |
Price to Book Ratio | 5.11 |
Enterprise Value to Revenue | 2.53 |
Enterprise Value to EBIT | 10.8 |
Enterprise Value to Net Income | 15 |
Total Debt to Enterprise | 0.23 |
Debt to Equity | 1.35 |
No data
No data